Contact
searchSearch
HMP Global
Login

Access Support Resource Center

Featured

News
HHS Final Rule Expands Real-Time Prescription Access, Eases Prior Authorization Burdens
09/26/2025
Grace Taylor, MS, MA
A sweeping new US Department of Health and Human Services (HHS) rule taking effect October 1 will give doctors and patients real-time access to drug costs and prior authorization decisions.
A sweeping new US Department of Health and Human Services (HHS) rule taking effect October 1 will give doctors and patients real-time access to drug costs and prior authorization decisions.
A sweeping new US Department of...
09/26/2025
Journal of Clinical Pathways
News
Virtual Screening Programs Expand Access to Cancer Screening Nationwide
06/13/2025
Grace Taylor, MS, MA
Virtual, community-based cancer screening programs significantly improve access to early detection services, especially in underserved populations, according to a study presented at the ASCO Annual Meeting.
Virtual, community-based cancer screening programs significantly improve access to early detection services, especially in underserved populations, according to a study presented at the ASCO Annual Meeting.
Virtual, community-based cancer...
06/13/2025
Journal of Clinical Pathways
News
Limited Access to Cancer Specialists Linked to Lower Treatment Rates and Higher Mortality in Early-Stage Lung Cancer
05/16/2025
Lisa Kuhns, PhD, MD
Patients with early-stage non–small cell lung cancer (NSCLC) living in areas with limited access to thoracic surgeons and radiation oncologists face lower treatment rates and higher cancer-related mortality, according to a population-based...
Patients with early-stage non–small cell lung cancer (NSCLC) living in areas with limited access to thoracic surgeons and radiation oncologists face lower treatment rates and higher cancer-related mortality, according to a population-based...
Patients with early-stage...
05/16/2025
Journal of Clinical Pathways
News
Many Older Americans Lack Local Access to Cancer Clinical Trials, Study Finds
05/09/2025
Lisa Kuhns, PhD, MD
Millions of older Americans live far from cancer clinical trial sites, limiting opportunities for participation in research that could shape future cancer care, according to a study published in JCO Clinical Practice.
Millions of older Americans live far from cancer clinical trial sites, limiting opportunities for participation in research that could shape future cancer care, according to a study published in JCO Clinical Practice.
Millions of older Americans live...
05/09/2025
Journal of Clinical Pathways
ACCESS SUPPORT
Access to Oncology Care: Bispecific Antibody Administration in Community Practices
04/15/2025
Winston Wong, PharmD
This column examines how although bispecific antibody (BsAb) treatments are transforming cancer care with greater efficacy, their complex risks demand careful coordination as patient care shifts away from hospitals.
This column examines how although bispecific antibody (BsAb) treatments are transforming cancer care with greater efficacy, their complex risks demand careful coordination as patient care shifts away from hospitals.
This column examines how...
04/15/2025
Journal of Clinical Pathways
News
Financial Strain Persists for Patients With Cancer Despite Support Referrals
04/04/2025
Grace Taylor, MS, MA
Despite targeted support, patients with cancer face ongoing and emerging financial toxicity and health-related social risks, underscoring the need for more sustainable interventions.
Despite targeted support, patients with cancer face ongoing and emerging financial toxicity and health-related social risks, underscoring the need for more sustainable interventions.
Despite targeted support,...
04/04/2025
Journal of Clinical Pathways
News
Improving Health Care Access for Immigrants With Disabilities in North America
03/14/2025
Hannah Musick
Exploring the barriers and facilitators of immigrants with disabilities accessing health care in the US and Canada, this qualitative meta-synthesis reveals the structural and cultural obstacles faced by this marginalized population and calls...
Exploring the barriers and facilitators of immigrants with disabilities accessing health care in the US and Canada, this qualitative meta-synthesis reveals the structural and cultural obstacles faced by this marginalized population and calls...
Exploring the barriers and...
03/14/2025
Journal of Clinical Pathways
News
Strategies to Enhance Cancer Screening Access for Patients With Disabilities
03/06/2025
Juliet Gallagher
Patients with disabilities face significant barriers to cancer screening, including communication challenges, physical inaccessibility, financial constraints, and provider assumptions, highlighting the need for targeted interventions to...
Patients with disabilities face significant barriers to cancer screening, including communication challenges, physical inaccessibility, financial constraints, and provider assumptions, highlighting the need for targeted interventions to...
Patients with disabilities face...
03/06/2025
Journal of Clinical Pathways
News
Large Language Models Aid in Simplifying Clinical Trial Information for Patients
02/19/2025
Grace Taylor, MS, MA
A recent study explores how artificial intelligence can generate accurate, patient-friendly summaries of cancer clinical trials, potentially improving enrollment and adherence.
A recent study explores how artificial intelligence can generate accurate, patient-friendly summaries of cancer clinical trials, potentially improving enrollment and adherence.
A recent study explores how...
02/19/2025
Journal of Clinical Pathways
News
Study Identifies Gaps and Opportunities in Community Engagement at Cancer Centers
01/22/2025
Juliet Gallagher
A study published in JNCI Cancer Spectrum highlights the challenges and opportunities for improving the impact of Community Outreach and Engagement (COE) programs at National Cancer Institute (NCI)-designated cancer centers.
A study published in JNCI Cancer Spectrum highlights the challenges and opportunities for improving the impact of Community Outreach and Engagement (COE) programs at National Cancer Institute (NCI)-designated cancer centers.
A study published in JNCI Cancer...
01/22/2025
Journal of Clinical Pathways
News
Social Risks Lower Rates of Preventive Cancer Screenings
01/09/2025
Juliet Gallagher
A recent study published in JNCI Cancer Spectrum investigated the pathways through which social risks affect screening outcomes for breast, cervical, and colorectal cancer (CRC) in patients served in community-based clinics across the US.
A recent study published in JNCI Cancer Spectrum investigated the pathways through which social risks affect screening outcomes for breast, cervical, and colorectal cancer (CRC) in patients served in community-based clinics across the US.
A recent study published in JNCI...
01/09/2025
Journal of Clinical Pathways

News

News
HHS Final Rule Expands Real-Time Prescription Access, Eases Prior Authorization Burdens
09/26/2025
Grace Taylor, MS, MA
A sweeping new US Department of Health and Human Services (HHS) rule taking effect October 1 will give doctors and patients real-time access to drug costs and prior authorization decisions.
A sweeping new US Department of Health and Human Services (HHS) rule taking effect October 1 will give doctors and patients real-time access to drug costs and prior authorization decisions.
A sweeping new US Department of...
09/26/2025
Journal of Clinical Pathways
News
Virtual Screening Programs Expand Access to Cancer Screening Nationwide
06/13/2025
Grace Taylor, MS, MA
Virtual, community-based cancer screening programs significantly improve access to early detection services, especially in underserved populations, according to a study presented at the ASCO Annual Meeting.
Virtual, community-based cancer screening programs significantly improve access to early detection services, especially in underserved populations, according to a study presented at the ASCO Annual Meeting.
Virtual, community-based cancer...
06/13/2025
Journal of Clinical Pathways
News
Limited Access to Cancer Specialists Linked to Lower Treatment Rates and Higher Mortality in Early-Stage Lung Cancer
05/16/2025
Lisa Kuhns, PhD, MD
Patients with early-stage non–small cell lung cancer (NSCLC) living in areas with limited access to thoracic surgeons and radiation oncologists face lower treatment rates and higher cancer-related mortality, according to a population-based...
Patients with early-stage non–small cell lung cancer (NSCLC) living in areas with limited access to thoracic surgeons and radiation oncologists face lower treatment rates and higher cancer-related mortality, according to a population-based...
Patients with early-stage...
05/16/2025
Journal of Clinical Pathways
News
Many Older Americans Lack Local Access to Cancer Clinical Trials, Study Finds
05/09/2025
Lisa Kuhns, PhD, MD
Millions of older Americans live far from cancer clinical trial sites, limiting opportunities for participation in research that could shape future cancer care, according to a study published in JCO Clinical Practice.
Millions of older Americans live far from cancer clinical trial sites, limiting opportunities for participation in research that could shape future cancer care, according to a study published in JCO Clinical Practice.
Millions of older Americans live...
05/09/2025
Journal of Clinical Pathways
News
Financial Strain Persists for Patients With Cancer Despite Support Referrals
04/04/2025
Grace Taylor, MS, MA
Despite targeted support, patients with cancer face ongoing and emerging financial toxicity and health-related social risks, underscoring the need for more sustainable interventions.
Despite targeted support, patients with cancer face ongoing and emerging financial toxicity and health-related social risks, underscoring the need for more sustainable interventions.
Despite targeted support,...
04/04/2025
Journal of Clinical Pathways
News
Improving Health Care Access for Immigrants With Disabilities in North America
03/14/2025
Hannah Musick
Exploring the barriers and facilitators of immigrants with disabilities accessing health care in the US and Canada, this qualitative meta-synthesis reveals the structural and cultural obstacles faced by this marginalized population and calls...
Exploring the barriers and facilitators of immigrants with disabilities accessing health care in the US and Canada, this qualitative meta-synthesis reveals the structural and cultural obstacles faced by this marginalized population and calls...
Exploring the barriers and...
03/14/2025
Journal of Clinical Pathways
News
Strategies to Enhance Cancer Screening Access for Patients With Disabilities
03/06/2025
Juliet Gallagher
Patients with disabilities face significant barriers to cancer screening, including communication challenges, physical inaccessibility, financial constraints, and provider assumptions, highlighting the need for targeted interventions to...
Patients with disabilities face significant barriers to cancer screening, including communication challenges, physical inaccessibility, financial constraints, and provider assumptions, highlighting the need for targeted interventions to...
Patients with disabilities face...
03/06/2025
Journal of Clinical Pathways
News
Large Language Models Aid in Simplifying Clinical Trial Information for Patients
02/19/2025
Grace Taylor, MS, MA
A recent study explores how artificial intelligence can generate accurate, patient-friendly summaries of cancer clinical trials, potentially improving enrollment and adherence.
A recent study explores how artificial intelligence can generate accurate, patient-friendly summaries of cancer clinical trials, potentially improving enrollment and adherence.
A recent study explores how...
02/19/2025
Journal of Clinical Pathways
News
Study Identifies Gaps and Opportunities in Community Engagement at Cancer Centers
01/22/2025
Juliet Gallagher
A study published in JNCI Cancer Spectrum highlights the challenges and opportunities for improving the impact of Community Outreach and Engagement (COE) programs at National Cancer Institute (NCI)-designated cancer centers.
A study published in JNCI Cancer Spectrum highlights the challenges and opportunities for improving the impact of Community Outreach and Engagement (COE) programs at National Cancer Institute (NCI)-designated cancer centers.
A study published in JNCI Cancer...
01/22/2025
Journal of Clinical Pathways
News
Social Risks Lower Rates of Preventive Cancer Screenings
01/09/2025
Juliet Gallagher
A recent study published in JNCI Cancer Spectrum investigated the pathways through which social risks affect screening outcomes for breast, cervical, and colorectal cancer (CRC) in patients served in community-based clinics across the US.
A recent study published in JNCI Cancer Spectrum investigated the pathways through which social risks affect screening outcomes for breast, cervical, and colorectal cancer (CRC) in patients served in community-based clinics across the US.
A recent study published in JNCI...
01/09/2025
Journal of Clinical Pathways
News
HHS Final Rule Expands Real-Time Prescription Access, Eases Prior Authorization Burdens
09/26/2025
Grace Taylor, MS, MA
A sweeping new US Department of Health and Human Services (HHS) rule taking effect October 1 will give doctors and patients real-time access to drug costs and prior authorization decisions.
A sweeping new US Department of Health and Human Services (HHS) rule taking effect October 1 will give doctors and patients real-time access to drug costs and prior authorization decisions.
A sweeping new US Department of...
09/26/2025
Journal of Clinical Pathways
News
NRF2 Inhibition Emerges as a Promising Strategy to Halt Esophageal Cancer Spread
08/13/2025
Lisa Kuhns, PhD, MD
Researchers have identified a promising new target to combat the deadly spread of esophageal squamous cell carcinoma (ESCC) by focusing on a master regulatory protein called NRF2, according to a study published in Cancers.
Researchers have identified a promising new target to combat the deadly spread of esophageal squamous cell carcinoma (ESCC) by focusing on a master regulatory protein called NRF2, according to a study published in Cancers.
Researchers have identified a...
08/13/2025
Journal of Clinical Pathways
News
Palliative Care Use Rose 24% in Medicare Cancer Decedents, but Disparities Persist
08/12/2025
Hannah Musick
Specialty palliative care use among Medicare decedents with poor-prognosis cancers grew significantly between 2018 and 2023. The change is driven by outpatient services, telehealth, and advanced practice clinicians—yet older adults,...
Specialty palliative care use among Medicare decedents with poor-prognosis cancers grew significantly between 2018 and 2023. The change is driven by outpatient services, telehealth, and advanced practice clinicians—yet older adults,...
Specialty palliative care use...
08/12/2025
Journal of Clinical Pathways
News
Perioperative Durvalumab-FLOT Regimen Demonstrates Superior Efficacy Over FLOT Alone
08/06/2025
Juliet Gallagher
A new phase 3 study published in the New England Journal of Medicine presents compelling evidence that perioperative durvalumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy significantly improves...
A new phase 3 study published in the New England Journal of Medicine presents compelling evidence that perioperative durvalumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy significantly improves...
A new phase 3 study published in...
08/06/2025
Journal of Clinical Pathways
News
Specialized Teams Improve Safety as Immunotherapy Use Surges in Cancer Care
07/30/2025
Lisa Kuhns, PhD, MD
As immunotherapy continues to transform cancer treatment, multidisciplinary teams are proving essential for managing the potentially severe toxicities that accompany these therapies, according to an article published in the American Society...
As immunotherapy continues to transform cancer treatment, multidisciplinary teams are proving essential for managing the potentially severe toxicities that accompany these therapies, according to an article published in the American Society...
As immunotherapy continues to...
07/30/2025
Journal of Clinical Pathways
News
NCCN Launches Interactive NCCN Guidelines Navigator to Advance Cancer Care Usability
07/11/2025
Grace Taylor, MS, MA
Discover how the National Comprehensive Cancer Network’s (NCCN) new digital Guidelines Navigator is transforming cancer care delivery with smarter, faster, and more accessible clinical guidelines.
Discover how the National Comprehensive Cancer Network’s (NCCN) new digital Guidelines Navigator is transforming cancer care delivery with smarter, faster, and more accessible clinical guidelines.
Discover how the National...
07/11/2025
Journal of Clinical Pathways
News
Study Finds Key Risk Factors for Gastric Cancer in US Patients With Chronic Gastritis
07/11/2025
Lisa Kuhns, PhD, MD
Adults under age 65 diagnosed with chronic atrophic gastritis (CAG) face a measurable risk of progressing to non-cardia gastric cancer (NCGC), with certain clinical and demographic factors significantly increasing that risk.
Adults under age 65 diagnosed with chronic atrophic gastritis (CAG) face a measurable risk of progressing to non-cardia gastric cancer (NCGC), with certain clinical and demographic factors significantly increasing that risk.
Adults under age 65 diagnosed...
07/11/2025
Journal of Clinical Pathways
News
Persistent Barriers in Gastric Cancer Care: GI Cancers Alliance Study
07/09/2025
Grace Taylor, MS, MA
A year-long study by the GI Cancers Alliance reveals critical gaps in gastric cancer care, highlighting persistent disparities in biomarker access, patient education, and mental health support.
A year-long study by the GI Cancers Alliance reveals critical gaps in gastric cancer care, highlighting persistent disparities in biomarker access, patient education, and mental health support.
A year-long study by the GI...
07/09/2025
Journal of Clinical Pathways
News
Nivolumab-Based Regimens Extend Survival in Advanced Gastroesophageal Cancer Based on Molecular Biomarkers
06/25/2025
Lisa Kuhns, PhD, MD
Nivolumab-based immunotherapy shows promise in extending survival for patients with advanced gastroesophageal adenocarcinoma, particularly in those with specific molecular and genomic profiles, according to study results published in Nature...
Nivolumab-based immunotherapy shows promise in extending survival for patients with advanced gastroesophageal adenocarcinoma, particularly in those with specific molecular and genomic profiles, according to study results published in Nature...
Nivolumab-based immunotherapy...
06/25/2025
Journal of Clinical Pathways
News
Study Shows Improved Outcomes in Older Adults With Mantle Cell Lymphoma Following Adoption of New Therapies
06/16/2025
Juliet Gallagher
New findings from a large, retrospective cohort study using SEER-Medicare data highlight improvements in survival outcomes over time among older adults with mantle cell lymphoma (MCL), likely associated with the adoption of novel therapeutic...
New findings from a large, retrospective cohort study using SEER-Medicare data highlight improvements in survival outcomes over time among older adults with mantle cell lymphoma (MCL), likely associated with the adoption of novel therapeutic...
New findings from a large,...
06/16/2025
Journal of Clinical Pathways

Interviews

Lee Fleisher, MD
Interview
CMS National Quality Strategy Focuses on Quality, Safety, Affordability Standards in Oncology Care
11/10/2022
Lee Fleisher, MD, outlines the foundation and goals of the Centers for Medicare and Medicaid Services’ National Quality Strategy, highlighting key components such as quality, safety, and affordability, and emphasizing alignment between all of...
Lee Fleisher, MD, outlines the foundation and goals of the Centers for Medicare and Medicaid Services’ National Quality Strategy, highlighting key components such as quality, safety, and affordability, and emphasizing alignment between all of...
Lee Fleisher, MD, outlines the...
11/10/2022
Journal of Clinical Pathways
Headshots
Interview
Endometrial Cancer Risk Research Suggests Earlier Intervention Across Age Groups
09/17/2025
Mengmeng Du, ScD, MSc; Noah C. Peeri, PhD, MPH
In this interview, guest cancer epidemiologists share their findings on endometrial cancer risk in younger women, highlighting the powerful role of obesity and metabolic health, shared risk patterns across age groups, and the importance of...
In this interview, guest cancer epidemiologists share their findings on endometrial cancer risk in younger women, highlighting the powerful role of obesity and metabolic health, shared risk patterns across age groups, and the importance of...
In this interview, guest cancer...
09/17/2025
Journal of Clinical Pathways
Thawani Headshot
Videos
Progression-Free Survival in NSCLC: Clinical Utility, Limitations, and Evolving Standards
08/28/2025
Rajat Thawani, MD
Rajat Thawani, MD, shares key insights on balancing progression-free and overall survival, the expanding role of biomarker testing, and the promise of multi-omic data integration in reshaping NSCLC treatment.
Rajat Thawani, MD, shares key insights on balancing progression-free and overall survival, the expanding role of biomarker testing, and the promise of multi-omic data integration in reshaping NSCLC treatment.
Rajat Thawani, MD, shares key...
08/28/2025
Journal of Clinical Pathways
ONLINE EXCLUSIVES
Developing a National Pathway Framework for Prostate Cancer: Insights From Solaris Health
08/15/2025
Jason Hafron, MD
Jason Hafron, MD, discusses how Solaris Health developed and implemented standardized, National Comprehensive Cancer Network (NCCN)-based prostate cancer pathways across its national network to ensure consistent, high-quality care, streamline...
Jason Hafron, MD, discusses how Solaris Health developed and implemented standardized, National Comprehensive Cancer Network (NCCN)-based prostate cancer pathways across its national network to ensure consistent, high-quality care, streamline...
Jason Hafron, MD, discusses how...
08/15/2025
Journal of Clinical Pathways
Jennifer Woyach, MD
Interview
Overcoming Resistance to Targeted Therapies in CLL Through Personalized Treatment Approaches
08/13/2025
Jennifer Ann Woyach, MD
This expert interview explores how emerging resistance mechanisms to Bruton tyrosine kinase (BTK) and BCL2 inhibitors are reshaping personalized treatment strategies and diagnostic workflows in chronic lymphocytic leukemia (CLL).
This expert interview explores how emerging resistance mechanisms to Bruton tyrosine kinase (BTK) and BCL2 inhibitors are reshaping personalized treatment strategies and diagnostic workflows in chronic lymphocytic leukemia (CLL).
This expert interview explores...
08/13/2025
Journal of Clinical Pathways
Interview
CPC+CBEx 2025 Is the Meeting Oncology Leaders Can’t Afford to Miss: A Q&A with Aimee Ginsburg Chesnick
08/04/2025
Aimee Ginsburg, PharmD, BCPS
As the pace of therapeutic advancement accelerates, the need to thoughtfully integrate novel treatments into real-world care settings is increasingly critical. In this Q&A, Steering Committee member and conference speaker Aimee Ginsburg...
As the pace of therapeutic advancement accelerates, the need to thoughtfully integrate novel treatments into real-world care settings is increasingly critical. In this Q&A, Steering Committee member and conference speaker Aimee Ginsburg...
As the pace of therapeutic...
08/04/2025
Journal of Clinical Pathways
Sledge
Interview
Reevaluating Tissue-Agnostic Therapies: Insights From a Real-World Genomic Analysis
07/25/2025
George W. Sledge, MD
In this interview, George W. Sledge, MD, explores the promise and limitations of tissue-agnostic cancer therapies, highlighting real-world disparities, biomarker variability, and the urgent need for better clinical decision support to guide...
In this interview, George W. Sledge, MD, explores the promise and limitations of tissue-agnostic cancer therapies, highlighting real-world disparities, biomarker variability, and the urgent need for better clinical decision support to guide...
In this interview, George W....
07/25/2025
Journal of Clinical Pathways
Dana Chase, MD
Interview
The Impact of Dostarlimab and Patient-Centered Outcomes in the RUBY Trial for Endometrial Cancer
07/24/2025
Dana M. Chase, MD, FACOG
Explore how dostarlimab combined with carboplatin-paclitaxel improves quality-adjusted time without symptoms of disease progression or treatment toxicity in patients with advanced or recurrent endometrial cancer.
Explore how dostarlimab combined with carboplatin-paclitaxel improves quality-adjusted time without symptoms of disease progression or treatment toxicity in patients with advanced or recurrent endometrial cancer.
Explore how dostarlimab combined...
07/24/2025
Journal of Clinical Pathways
Zunairah Shah, MD
Interview
Addressing Racial Disparities in HER2-Positive Breast Cancer Outcomes
07/23/2025
Zunairah Shah, MD
Explore how real-world data reveals critical racial and ethnic survival disparities in HER2-positive breast cancer treatment and what can be done to close the gap.
Explore how real-world data reveals critical racial and ethnic survival disparities in HER2-positive breast cancer treatment and what can be done to close the gap.
Explore how real-world data...
07/23/2025
Journal of Clinical Pathways
Korentager Headshot
Interview
Integrating Lymphedema Prevention Into Oncology Pathways: Insights From Oncology Nursing
06/27/2025
Sabrina Korentager, MSN, BS, RN
Veteran oncology nurse Sabrina Korentager shares her passionate journey into lymphedema prevention, emphasizing the transformative impact of early detection, patient education, and nurse-led care coordination in elevating survivorship...
Veteran oncology nurse Sabrina Korentager shares her passionate journey into lymphedema prevention, emphasizing the transformative impact of early detection, patient education, and nurse-led care coordination in elevating survivorship...
Veteran oncology nurse Sabrina...
06/27/2025
Journal of Clinical Pathways
David M. O'Malley, MD
Interview
Relacorilant Plus Nab-Paclitaxel Shows Promising Survival Benefit in Platinum-Resistant Ovarian Cancer: ROSELLA Trial
06/24/2025
David O'Malley
The phase 3 ROSELLA trial highlights the potential of relacorilant combined with nab-paclitaxel to improve survival outcomes in patients with platinum-resistant ovarian cancer.
The phase 3 ROSELLA trial highlights the potential of relacorilant combined with nab-paclitaxel to improve survival outcomes in patients with platinum-resistant ovarian cancer.
The phase 3 ROSELLA trial...
06/24/2025
Journal of Clinical Pathways

Blog

Jacqlyn Riposo
Quality Outlook
Focus on Outcomes: Quality Measurement Recommendations for CMS’ Medicaid Cell and Gene Therapy Access Model
06/08/2023
Tom Valuck, MD, JD; Jacqlyn Riposo, MBA
This blog discusses the Centers for Medicare and Medicaid Services new cell and Gene Therapy Access Model proposal and recommends different ways the Center for Medicare and Medicaid Innovation can apply quality measurement to cell and gene...
This blog discusses the Centers for Medicare and Medicaid Services new cell and Gene Therapy Access Model proposal and recommends different ways the Center for Medicare and Medicaid Innovation can apply quality measurement to cell and gene...
This blog discusses the Centers...
06/08/2023
Journal of Clinical Pathways
Sarena Ho, MSPH
Quality Outlook
Quality Measures for Medicare’s Enhancing Oncology Model (EOM): New and Improved or More of the Same?
01/26/2023
David Blaisdell, BA; Tom Valuck, MD, JD; Sarena Ho, MSPH
This blog discusses the Center for Medicare & Medicaid Service’s efforts to advance cancer quality through its new Enhancing Oncology Model (EOM) and presents recommendations for strengthening the EOM measure set and aligning measures across...
This blog discusses the Center for Medicare & Medicaid Service’s efforts to advance cancer quality through its new Enhancing Oncology Model (EOM) and presents recommendations for strengthening the EOM measure set and aligning measures across...
This blog discusses the Center...
01/26/2023
Journal of Clinical Pathways
Blog
CPC+CBEx 2025 Abstracts: Business Models, Breakthrough Tools, and Data-Driven Decisions Driving the Future of Cancer Care
08/27/2025
The 2025 Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), to be held September 5-6 in Boston, will confront these challenges head-on through 13 powerful abstracts that demonstrate what it takes to translate evidence into...
The 2025 Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), to be held September 5-6 in Boston, will confront these challenges head-on through 13 powerful abstracts that demonstrate what it takes to translate evidence into...
The 2025 Clinical Pathways...
08/27/2025
Journal of Clinical Pathways
Quality Outlook
Every Second Counts: the Impact of FDA’s Accelerated Approval Program
03/05/2025
Bridget Doherty, MPH, MS; Silas Martin, MS; Tom Valuck, MD, JD
Johnson & Johnson’s research highlights the significant impact of the FDA’s Accelerated Approval Program, estimating that earlier access to cancer therapies has provided approximately 263 000 additional life years to patients, reinforcing the...
Johnson & Johnson’s research highlights the significant impact of the FDA’s Accelerated Approval Program, estimating that earlier access to cancer therapies has provided approximately 263 000 additional life years to patients, reinforcing the...
Johnson & Johnson’s research...
03/05/2025
Journal of Clinical Pathways
CPC + CBEx: Breaking down barriers and pushing boundaries of cancer care
Blog
CPC + CBEx: Breaking down barriers and pushing boundaries of cancer care
08/07/2024
Winston Wong, PharmD
At CPC+CBEx, we bring together stakeholders invested throughout the entire patient journey.
At CPC+CBEx, we bring together stakeholders invested throughout the entire patient journey.
At CPC+CBEx, we bring together...
08/07/2024
Journal of Clinical Pathways
Editor in chief Winston Wong, PharmD.
Editor Insights
Looking at 2023 Key Trends and Insights to Navigate the Future of Value-Based Care
02/13/2024
Winston Wong, PharmD
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature...
02/13/2024
Journal of Clinical Pathways
Kendall Logan, MPH.
Quality Outlook
A Tale of Two States: Examining the Best and Worst Performing States for HPV Vaccination
02/12/2024
Anne DiSalvo, MPH, MBA; Kendall Logan, MPH; Erik Muther; Tom Valuck, MD, JD
This blog post is the last in a three-part series exploring the disparities related to human papilloma virus (HPV) vaccination rates in the US.
This blog post is the last in a three-part series exploring the disparities related to human papilloma virus (HPV) vaccination rates in the US.
This blog post is the last in a...
02/12/2024
Journal of Clinical Pathways
Theresa Schmidt headshot.
Quality Outlook
2024 Quality Outlook Revealed: Insights from 2023 Fall Conferences
02/02/2024
Tom Valuck, MD, JD; Erik Muther; Theresa Schmidt, MA, PMP, CSPO; Danny Bellet, MBA; Donna Dugan, PhD, MS; David Sloan, PhD
This past fall, leaders from the Real Chemistry Market Access team attended key quality-related events to understand trends and learn from other quality and value experts.
This past fall, leaders from the Real Chemistry Market Access team attended key quality-related events to understand trends and learn from other quality and value experts.
This past fall, leaders from the...
02/02/2024
Journal of Clinical Pathways
Anne Disalvo headshot
Quality Outlook
Saving Lives from Preventable Cancer: Solutions for Racial and Ethnic Disparities in HPV Vaccination
11/10/2023
Tom Valuck, MD, JD; Anne DiSalvo, MPH, MBA; Kendall Logan, MPH; Erik Muther
This is the second part of a 3-part blog series that explores issues related to HPV vaccination rates in the US. In this blog, the racial and ethnic disparities in HPV vaccination are explored.
This is the second part of a 3-part blog series that explores issues related to HPV vaccination rates in the US. In this blog, the racial and ethnic disparities in HPV vaccination are explored.
This is the second part of a...
11/10/2023
Journal of Clinical Pathways
Anne DiSalvo.
Quality Outlook
Saving Lives from Preventable Cancer: Solutions for Geographic Disparities in HPV Vaccination
10/03/2023
Tom Valuck, MD, JD; Anne DiSalvo, MPH, MBA; Kendall Logan, MPH; Erik Muther
This is the first of a 3-part blog series that explores issues related to HPV vaccination rates in the US. In this blog, vaccination disparities are explored among the highest and lowest performing states.
This is the first of a 3-part blog series that explores issues related to HPV vaccination rates in the US. In this blog, vaccination disparities are explored among the highest and lowest performing states.
This is the first of a 3-part...
10/03/2023
Journal of Clinical Pathways
David Blaisdell, BA, Real Chemistry.
Quality Outlook
Enhancing Value-Based Oncology Care: What Has CMMI Learned From the OCM?
09/22/2023
David Blaisdell, BA; Tom Valuck, MD, JD
We previously wrote about lessons from the Oncology Care Model (OCM) that the Center for Medicare and Medicaid Innovation (CMMI) could apply to the Enhancing Oncology Model (EOM). Subsequently, CMMI recently released an evaluation report for...
We previously wrote about lessons from the Oncology Care Model (OCM) that the Center for Medicare and Medicaid Innovation (CMMI) could apply to the Enhancing Oncology Model (EOM). Subsequently, CMMI recently released an evaluation report for...
We previously wrote about...
09/22/2023
Journal of Clinical Pathways
Jacqlyn Riposo
Quality Outlook
Focus on Outcomes: Quality Measurement Recommendations for CMS’ Medicaid Cell and Gene Therapy Access Model
06/08/2023
Tom Valuck, MD, JD; Jacqlyn Riposo, MBA
This blog discusses the Centers for Medicare and Medicaid Services new cell and Gene Therapy Access Model proposal and recommends different ways the Center for Medicare and Medicaid Innovation can apply quality measurement to cell and gene...
This blog discusses the Centers for Medicare and Medicaid Services new cell and Gene Therapy Access Model proposal and recommends different ways the Center for Medicare and Medicaid Innovation can apply quality measurement to cell and gene...
This blog discusses the Centers...
06/08/2023
Journal of Clinical Pathways

Videos

Laura Bray
Videos
Advocacy to Reduce the Impact of Drug Shortages on Cancer Care
07/23/2024
Laura Bray, MBA
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her...
07/23/2024
Journal of Clinical Pathways
Video preview image.
Videos
St. Elizabeth’s Innovative Cancer Screening Outreach Model
09/22/2023
Michael Gieske, MD; Jamie Ries, BSN, RN
Michael Gieske, MD, and Jamie Ries, RN, BSN, speak about the development of a care delivery model that demonstrates sustainable outreach for cancer screening, with a specific focus on at-risk and underserved patient populations.
Michael Gieske, MD, and Jamie Ries, RN, BSN, speak about the development of a care delivery model that demonstrates sustainable outreach for cancer screening, with a specific focus on at-risk and underserved patient populations.
Michael Gieske, MD, and Jamie...
09/22/2023
Journal of Clinical Pathways
Puneeth Indurlal, MD
Videos
Impact of Dose Rounding Bevacizumab and its Biosimilars on Total Cost of Care for OCM Participants
07/26/2023
Puneeth Indurlal, MD
Puneeth Indurlal, MD, discusses the impact of dose rounding that targets bevacizumab and its biosimilars on the total cost of care and drug waste expenditures for Oncology Care Model participants in the US Oncology Network.
Puneeth Indurlal, MD, discusses the impact of dose rounding that targets bevacizumab and its biosimilars on the total cost of care and drug waste expenditures for Oncology Care Model participants in the US Oncology Network.
Puneeth Indurlal, MD, discusses...
07/26/2023
Journal of Clinical Pathways
Monica Schmidt, PhD.
Videos
The Impact of Elsevier ClinicalPath Oncology Treatment Pathways on Survival and Cost of Care
07/24/2023
Monica Schmidt, PhD
In an interview with the Journal of Clinical Pathways, Monica Schmidt, PhD, MPH, discusses her study on the impact of using Elsevier’s ClinicalPath oncology pathways on short-term survival and cost of care from the patient and health system...
In an interview with the Journal of Clinical Pathways, Monica Schmidt, PhD, MPH, discusses her study on the impact of using Elsevier’s ClinicalPath oncology pathways on short-term survival and cost of care from the patient and health system...
In an interview with the Journal...
07/24/2023
Journal of Clinical Pathways
Aaron P. Mitchell, MD, MPH
Videos
Study Examines the Association Between Oncologists’ Receipt of Pharmaceutical Industry Payments and Use of Nonrecommended/Low-Value Treatments
07/20/2023
Aaron P. Mitchell, MD
Aaron P. Mitchell, MD, MPH, discusses his research on the association of pharmaceutical industry payments to oncologists and their increased use of nonrecommended and/or low-value treatment methods.
Aaron P. Mitchell, MD, MPH, discusses his research on the association of pharmaceutical industry payments to oncologists and their increased use of nonrecommended and/or low-value treatment methods.
Aaron P. Mitchell, MD, MPH,...
07/20/2023
Journal of Clinical Pathways
Patricia Santos, MD
Videos
Health Care Access and Affordability for Adult Immigrant Cancer Survivors
06/26/2023
Patricia Santos, MD
Patricia Santos, MD, Memorial Sloan Kettering Cancer Center, spoke with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting about her research on the coverage and affordability of health care access for adult immigrant cancer...
Patricia Santos, MD, Memorial Sloan Kettering Cancer Center, spoke with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting about her research on the coverage and affordability of health care access for adult immigrant cancer...
Patricia Santos, MD, Memorial...
06/26/2023
Journal of Clinical Pathways
Lalan Wilfong, MD.
Conference Coverage
Benefits and Challenges of the Enhancing Oncology Model
06/13/2023
At the ASCO 2023 Annual Meeting, Lalan Wilfong, MD, provided an overview of the Enhancing Oncology Model and how it differs from and improves upon the Oncology Care Model.
At the ASCO 2023 Annual Meeting, Lalan Wilfong, MD, provided an overview of the Enhancing Oncology Model and how it differs from and improves upon the Oncology Care Model.
At the ASCO 2023 Annual Meeting,...
06/13/2023
Journal of Clinical Pathways
Dr Daniel Virnich, President, the Oncology Institute.
Videos
A Value-based Framework for Drug Cost Support and Funding Programs
05/11/2023
Dr Daniel Virnich, President, The Oncology Institute, discusses his presentation on drug cost support and funding programs for patients with cancer from Oncology at Total Health 2022.
Dr Daniel Virnich, President, The Oncology Institute, discusses his presentation on drug cost support and funding programs for patients with cancer from Oncology at Total Health 2022.
Dr Daniel Virnich, President,...
05/11/2023
Journal of Clinical Pathways
Adria Warren, Partner at Foley & Lardner LLP
Videos
New Developments in the 340B Drug Pricing Program
04/03/2023
Adria Warren, health care transactional partner at Foley & Lardner LLP, spoke with the Journal of Clinical Pathways about new developments in the 340B drug pricing program and provided updates on recent court rulings and cases in process that...
Adria Warren, health care transactional partner at Foley & Lardner LLP, spoke with the Journal of Clinical Pathways about new developments in the 340B drug pricing program and provided updates on recent court rulings and cases in process that...
Adria Warren, health care...
04/03/2023
Journal of Clinical Pathways
Lee Fleisher, MD
Videos
Making Clinical Pathways Unique to the Patient Journey
11/14/2022
Lee Fleisher, MD, discusses balancing the need for uniform quality care for all patients with finding the proper pathways for individual patients.
Lee Fleisher, MD, discusses balancing the need for uniform quality care for all patients with finding the proper pathways for individual patients.
Lee Fleisher, MD, discusses...
11/14/2022
Journal of Clinical Pathways
BDHC thumbnail
Videos
Second Opinions in Oncology: Quality, Communication, and Patient Confidence
09/16/2025
John Hennessy, MBA; Michael Kolodziej, MD
In this episode of Breaking Down Health Care, John Hennessy and Dr Michael Kolodziej explore the many dimensions of second opinions in oncology—ranging from in-practice consultations to academic referrals, payer-sponsored programs, and...
In this episode of Breaking Down Health Care, John Hennessy and Dr Michael Kolodziej explore the many dimensions of second opinions in oncology—ranging from in-practice consultations to academic referrals, payer-sponsored programs, and...
In this episode of Breaking Down...
09/16/2025
Cancer Care Business Exchange
Golla Headshot
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
09/10/2025
Vishnukamal Golla, MD, MPH
In this discussion, Dr Kamal Golla, vice president of clinical technology and performance at Evolent Health, shares how the Predictable Cost of Care model shifts the focus from drug acquisition costs to a comprehensive view of total care...
In this discussion, Dr Kamal Golla, vice president of clinical technology and performance at Evolent Health, shares how the Predictable Cost of Care model shifts the focus from drug acquisition costs to a comprehensive view of total care...
In this discussion, Dr Kamal...
09/10/2025
Journal of Clinical Pathways
Thawani Headshot
Videos
Progression-Free Survival in NSCLC: Clinical Utility, Limitations, and Evolving Standards
08/28/2025
Rajat Thawani, MD
Rajat Thawani, MD, shares key insights on balancing progression-free and overall survival, the expanding role of biomarker testing, and the promise of multi-omic data integration in reshaping NSCLC treatment.
Rajat Thawani, MD, shares key insights on balancing progression-free and overall survival, the expanding role of biomarker testing, and the promise of multi-omic data integration in reshaping NSCLC treatment.
Rajat Thawani, MD, shares key...
08/28/2025
Journal of Clinical Pathways
Wilfong Headshot
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
08/20/2025
Lalan Wilfong, MD
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care...
08/20/2025
Journal of Clinical Pathways
Henschel
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
08/13/2025
Rhonda Henschel, MBA
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care...
08/13/2025
Journal of Clinical Pathways
Arrowsmith Headshot
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
08/08/2025
Edward Arrowsmith, MD
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care...
08/08/2025
Journal of Clinical Pathways
BDHC thumbnail
Videos
Recognizing the Importance of Primary Care in Cancer Care Delivery
08/04/2025
John Hennessy, MBA; Michael Kolodziej, MD
In this episode of Breaking Down Health Care, John Hennessy and Dr Michael Kolodziej explore the undervalued yet critical role of primary care in the health care ecosystem—especially in oncology—highlighting its impact on early detection,...
In this episode of Breaking Down Health Care, John Hennessy and Dr Michael Kolodziej explore the undervalued yet critical role of primary care in the health care ecosystem—especially in oncology—highlighting its impact on early detection,...
In this episode of Breaking Down...
08/04/2025
Cancer Care Business Exchange
Videos
Driving Innovation in Care With Edward Arrowsmith, MD, and the Predictable Cost of Care Working Group
07/28/2025
Edward Arrowsmith, MD
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care...
07/28/2025
Journal of Clinical Pathways
Chau and VanGalder Headshots
Videos
Understanding Clinical Pathways: Quality, Cost, and Collaboration
07/25/2025
Amy VanGalder, PharmD, BCOP; Sang Chau, PharmD, BCOP
Two oncology pharmacy leaders from Evolent discuss how clinical pathways—grounded in evidence and integrated with technology—are transforming cancer care by improving quality, reducing costs, and aligning with value-based care models.
Two oncology pharmacy leaders from Evolent discuss how clinical pathways—grounded in evidence and integrated with technology—are transforming cancer care by improving quality, reducing costs, and aligning with value-based care models.
Two oncology pharmacy leaders...
07/25/2025
Journal of Clinical Pathways
Videos
Driving Innovation in Care With Lalan Wilfong, MD, and the Predictable Cost of Care Working Group
07/25/2025
Lalan Wilfong, MD
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care...
07/25/2025
Journal of Clinical Pathways
JCP July-Aug Cover 2025

Current Issue

August 2025
Volume 11
Issue 4
Current Issue
Issue Archive

Special Reports

Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use